SAA holds an organizational meeting for U.S. researchers to establish the Spondyloarthritis Research and Treatment Network (SPARTAN) for the purpose of advancing clinical research of spondyloarthritis in the United States.
SAA offers its first accredited Continuing Medical Education (CME) program for physicians titled, “Ankylosing Spondylitis & Related Spondyloarthropathies: Aggressive Management of Aggressive Diseases.”
Jane Bruckel testifies at an FDA hearing to advocate for approval of Enbrel as the first biologic drug for AS.